Background Metabolomics, defined as the comprehensive identification and quantification of low-molecular-weight metabolites to be found in a biological sample, has been put forward as a potential tool for classifying individuals according to their risk of coronary heart disease (CHD). Here, we investigated whether a single-point blood measurement of the metabolome is associated with and predictive for the risk of CHD.
Methods and results
We obtained proton nuclear magnetic resonance spectra in 79 cases who developed CHD during follow-up (median 8.1 years) and in 565 randomly selected individuals. In these spectra, 100 signals representing 36 metabolites were identified. Applying least absolute shrinkage and selection operator regression, we defined a weighted metabolite score consisting of 13 proton nuclear magnetic resonance signals that optimally predicted CHD. This metabolite score, including signals representing a lipid fraction, glucose, valine, ornithine, glutamate, creatinine, glycoproteins, citrate, and 1.5-anhydrosorbitol, was associated with the incidence of CHD independent of traditional risk factors (TRFs) (hazard ratio 1.50, 95% CI 1.12-2.01). Predictive performance of this metabolite score on its own was moderate (C-index 0.75, 95% CI 0.70-0.80), but after adding age and sex, the C-index was only modestly lower than that of TRFs (C-index 0.81, 95% CI 0.77-0.85 and C-index 0.82, 95% CI 0.78-0.87, respectively). The metabolite score was also associated with prevalent CHD independent of TRFs (odds ratio 1.59, 95% CI 1.19-2.13).
Conclusion A metabolite score derived from a single-point metabolome measurement is associated with CHD, and metabolomics may be a promising tool for refining and improving the prediction of CHD. (Am Heart J 2014;168:45-52.e7.)
Over the last 50 years, risk factors that are robustly and independently associated with coronary heart disease (CHD), including lipid levels, blood pressure, lifestyle factors, family history, sex, and age, were identified. 1, 2 Based on these traditional risk factors (TRFs), scores have been developed to predict CHD risk for an individual. 1, 2 The discriminatory capabilities for these scores, as assessed by the C-index, ranges from 0.71 to 0.84.
Metabolomics refers to the identification and quantification of low-molecular-weight metabolites in a biological sample. 3 Recent technological developments made it possible to generate metabolomic profiles of blood samples consisting of 10s to 100s metabolites in a single measurement. 4 These profiles are considered to be promising tools to efficiently capture the predictive information of TRFs and may potentially contribute to further improvement of primary CHD risk prediction. 3 Several studies have attempted to use a metabolomic approach to diagnose prevalent CHD 5, 6 or to predict incident CHD events in individuals free from cardiovascular disease [7] [8] [9] or diagnosed with CHD [10] [11] [12] [13] or diabetes. 14 According to some studies a metabolomic approach might improve CHD risk prediction. [8] [9] [10] [11] [12] [13] For example, in 1 study, proton nuclear magnetic resonance ( 1 H-NMR) spectroscopy improves the prediction of subclinical atherosclerosis in comparison with conventional lipid testing. 8 Other studies found that a baseline metabolomic profile based on mass spectroscopy was associated with incident cardiovascular events in patients diagnosed with CHD 11 or in patients with suspected CHD. 10, 12, 13 However, none of these studies investigated if a metabolite profile based on low-molecular-weight molecules identified by 1 H-NMR spectroscopy could predict incident CHD, defined as an acute myocardial infarction (MI), unstable angina pectoris (UAP), or dead because of CHD, in individuals free from cardiovascular disease. Therefore, we studied the association of an 1 H-NMR based metabolite profile with incident CHD in a prospective case-cohort study. Subsequently, a second study was performed in an independent population to test if the selected metabolites were also relevant to classify prevalent CHD.
Materials and methods

Study populations
Primary study. We conducted a prospective casecohort study within the Monitoring Project on Chronic Disease Risk Factors 1993 to 1997, 15 1 of the 2 monitoring studies that were included in the Cardiovascular Registry Maastricht study. 16 In total, 6,459 men and women, between 20 and 59 years old at the moment of inclusion, had given informed consent to retrieve information from the municipal registries and from the general practitioner and specialist. The study complied with the Declaration of Helsinki and was approved by the Medical Ethics Committee of TNO (Dutch Organization for Applied Scientific Research). We excluded participants who were younger than 30 years at baseline (n = 1,301); who had had an acute MI, UAP, a coronary artery bypass graft, or a percutaneous transluminal coronary angioplasty before baseline (n = 69); or were lost to follow-up (n = 15), resulting in an eligible cohort of 5,074 participants. Determination of TRFs. At baseline, participants filled in a questionnaire on medical history (including selfreported diabetes), parental history of MI (defined as no parents with MI, 1 parent with MI, or both parents with MI), and lifestyle factors (including smoking). During a medical examination, information on SBP and BMI was collected, and nonfasting EDTA blood samples were taken. 17, 18 The blood was centrifuged for 10 minutes at 1000 rpm at 4°C, and EDTA plasma aliquots were stored at −80°C in tubes of 0.5 mL for future analysis or at −20°C for cholesterol determinations. High-density lipoprotein cholesterol and TC levels were determined in the plasma samples stored at −20°C using a Cholesterol oxidase/4-aminophenazone (CHOD-PAP) method. 19 Secondary study. The Erasmus Rucphen Family study is a population-based study in a genetically isolated community in the Southwest of the Netherlands and includes 3,465 individuals, who are living descendants of 22 couples that had at least 6 children baptized in the community church between 1850 and 1900. Details are described elsewhere. 20 The study was approved by the Medical Ethical Committee of the Erasmus Medical Center in Rotterdam, and all participants gave written informed consent.
Determination of TRFs All participants filled in questionnaires about lifestyle, personal, and family medical history. During personal interviews performed by study physicians, information on lifestyle factors, medication use, and personal and family medical history was collected. Physical examinations were performed, including measurements of SBP and BMI. 21 In addition, fasted blood samples were taken. An electrocardiogram was performed and scored by an experienced cardiologist. Plasma concentrations of HDL-C and TC were determined according to standard procedures. 22 Diabetes was defined as the use of blood glucose-lowering medication and/or fasting glucose levels of ≥7 mmol/L.
Diagnosis of CHD in the secondary study. Participants were classified as CHD cases if they indicated during the interview or in the questionnaire that they had experienced an MI or underwent a coronary revascularization procedure, they reported angina symptoms in the interview, and/or showed signs of MI on electrocardiogram.
From 2,919 participants, fasting serum samples were available. Good-quality 1 H-NMR spectra from 2,415 participants were obtained. For 2,327 of these participants, data on CHD diagnosis were available, and 170 were classified as having CHD.
H-NMR metabolite profiling
The stored EDTA plasma and serum samples were thawed at 4°C and were mixed by inverting the tubes 10 times. Next, samples (300 μL) were mixed with 300 μL sodium 3-[trimethylsilyl] d 4 -propionate buffer (see online Appendix Supplementary material) and transferred into 5-mm nuclear magnetic resonance tubes and kept at 6°C while queued for acquisition. Two-dimensional J-resolved and Carr-Purcell-Meiboom-Gill spectra were acquired on a 600-MHz Bruker Avance II spectrometer (Bruker BioSpin, Karlsruhe, Germany), operating at a sample temperature of 310 K. For details on acquisition, processing, quality control, scaling, and calibration of the 1 H-NMR spectra, see online Appendix Supplementary methods.
Using the procedure described in the online Appendix Supplementary material, 100 signals were detected and quantified in the 1 H-NMR spectra of every individual in the primary study. For 76 signals, metabolites were assigned (see online Appendix Supplementary methods and online Appendix Supplementary Table I for all 1 H-NMR signals and their assigned metabolites). These signals represented 36 different compounds (ie, after subtracting the signals representing free EDTA). Signals representing calcium-EDTA and magnesium-EDTA complexes may give an indication of the levels of calcium and magnesium ions, respectively. Using the same procedure, 68 of 100 signals detected in the primary study were detected in the secondary study. For 54 of these 68 signals, metabolites could be assigned, representing 28 different compounds.
Statistical analysis
In the primary study, Cox regression, adjusted for delayed entry, and according to the method of Prentice to adjust for the case-cohort design was performed to see whether baseline characteristics were associated with incident CHD. 23 Age in years was used as the timescale variable. Before analysis, the 1 H-NMR signals were transformed to Z-scores. We selected a subset of the most informative signals for CHD prediction, using least absolute shrinkage and selection operator (LASSO) regression, 24 and performed 10-fold cross-validation to determine the tuning parameter. 24, 25 This set was further reduced to signals that could be detected in both studies. The linear predictor of the Cox model was used as a weighted metabolite score (sum of regression coefficients multiplied by the corresponding covariate values).
Cox regression, according to the method of Prentice to adjust for the case-cohort design, was used to calculate whether this metabolite score was associated with incident CHD before and after adjusting for TRFs. 23 To investigate whether the metabolite score improved risk discrimination, Harrell's concordance index (Cindex), 26 the net reclassification index (NRI), and the integrative discrimination index (IDI) were calculated. 27 For the NRI, the following risk categories were applied: 0% to b5%, 5% to b10%, 10% to b20%, ≥20%. Next, using analysis of variance, we investigated to what extent TRFs can explain the variance in the metabolite score in the subcohort. Stata/ SE version 11.2 was used to calculate the C-index. R-package PredictABEL version 1.2-1 was used to calculate the IDI. For all other analyses, R version 2.14.1 was used.
In the secondary study, raw 1 H-NMR signal data were adjusted for kinship by linear regression in GenABEL. 28 The residuals for all signals were transformed into Zscores. Logistic regression was performed to assess the association of TRFs with prevalent CHD. To assess whether the metabolite signals selected by LASSO regression in the primary study were also relevant for the identification of prevalent CHD cases, we put these signals into one logistic regression model to determine their individual regression coefficients. Next, we used logistic regression analysis to test the association of this metabolite score, thus with weights based on the secondary study, with prevalent CHD. Finally, we tested to what extent TRFs can explain the variance in the metabolite score using analysis of variance. For these analyses, PASW statistics version 18 (SPSS-IBM, Chicago, IL) was used.
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Results
Primary study
The TRFs were associated with incident CHD. When all TRFs were entered into a Cox proportional hazards model with age in years as the time-scale variable, HDL-C, SBP, sex, and current smoking remained independently associated with incident CHD (Table I) . See online Appendix Supplementary Table II for Table I. We determined 16 1 H-NMR signals as the best prediction subset using LASSO regression, of which 13 were available in the secondary study ( Figure 1 ). These 16 1 H-NMR signals represent creatinine, serine, glucose, 1,5-anhydrosorbitol, trimethylamine N-oxide (TMAO), ornithine, citrate, glutamate, glycoproteins, an unsaturated lipid structure, valine, and 5 nonannotated signals located at 3.924, 3.145, 2.412, 1.391, and 0.988 ppm. From the 13 signals present in both the primary and secondary study, a weighted metabolite score was constructed using the corresponding coefficients ( Figure 1 ). This metabolite score was normally distributed in cases and subcohort members (online Appendix Supplementary Figure) and associated with incident CHD (hazard ratio [HR] per SD 1.91, 95% CI 1.50-2.44). After adjusting for TRFs, this metabolite score remained associated with incident CHD (HR/SD 1.50, 95% CI 1.12-2.01). For the results of the metabolite score based on the 16 signals, see online Appendix Supplementary Table III. The metabolite score had a C-index of 0.75 (95% CI 0.70-0.80). Adding age and sex to the metabolite score, resulted in a C-index of 0.81 (95% CI 0.77-0.85), which is similar to a C-index when only TRFs are included (Cindex 0.82, 95% CI 0.78-0.87, P = .327). When the metabolite score was added to a model containing all TRFs, the C-index increased from 0.82 to 0.84, which was nonsignificant (P = .107). Both the improvement in the NRI (NRI total = 0.038, P = .209) and the IDI (0.012, P = .091) were nonsignificant (online Appendix Supplementary Tables IV and V) . Inspecting C-indices for individual TRFs and evaluating improvement of adding the metabolite score indicated that the metabolite score improved the C-indices of all individual TRFs (online Appendix Supplementary Table VI) .
We tested to what extent TRFs explain the variance in the metabolite score in the subcohort of the primary study. High-density lipoprotein cholesterol, sex, BMI, TC, SBP, age, and diabetes explained respective 16.4%, 11.7%, 10.0%, 7.9%, 5.6%, 4.1%, and 2.3% of the variance in the metabolite score. Current smoking and parental history of MI all explained b1% of the variance in the metabolite score ( Figure 2 ). When all TRFs were combined, 32.6% of the variance in the metabolite score was explained.
Secondary study
To test if the 13 metabolite signals selected in the primary study were relevant for the identification of prevalent CHD cases, we investigated 170 CHD cases and 2,157 controls for which equivalent metabolomics profiles were obtained. In this nonprospective cohort, combining all TRFs in 1 logistic regression model resulted in only age, sex, and parental history of MI to be independently associated with prevalent CHD (Table II) . See online Appendix Supplementary Table VII for the baseline characteristics before excluding individuals with missing data. The metabolite score, based on the 13 best predicting signals in the case-cohort study, but with weights based on the secondary study (Figure 2 ), was associated with prevalent CHD before (odd ratio [OR] 2.72, P b .001) and after adjusting for TRFs (OR 1.59, P = .002). After excluding statin users (n = 299), similar results were obtained (online Appendix Supplementary Table VIII) .
The proportion of variance in the metabolite score explained by age, SBP, and diabetes was higher for the secondary study than for primary study, whereas the variables TC, HDL-C, and BMI explained a lower proportion of the variance (Figure 2 ). The proportion of variance explained by sex, current smoking, and parental history of MI was comparable for both studies. With all TRFs combined, 27.3% of the variance of the metabolite score could be explained, which is comparable with that of the primary study.
Discussion
A metabolite score, based on 1 H-NMR spectroscopy, is significantly associated with incident CHD independent of TRFs. When combined with age and sex, this score was as predictive for incident CHD as all TRFs combined. A score based on the same 1 H-NMR signals was also associated with prevalent CHD, independent of TRFs.
The observation that the metabolite score could not improve CHD risk prediction beyond TRFs in individuals free from CHD is in line with a previous study published by El Harchaoui et al. 7 However, Würtz et al 8 found that metabolites measured by 1 H-NMR spectroscopy improved risk stratification for subclinical atherosclerosis in comparison with conventional lipids. In this study, both 1 H-NMR determined lipoproteins and lowmolecular-weight metabolites were included. 8 We only included information on low-molecular-weight metabolites, whereas in the study by El Harchaoui et al, only information on lipoproteins was included. Perhaps the combination of both lipoproteins and low-molecularweight metabolites results in the optimal prediction of CHD.
The metabolite score represents the metabolites valine, ornithine, glucose, 1.5-anhydrosorbitol, creatinine, an unsaturated lipid structure, glutamate, glycoproteins, citrate, and TMAO, of which TMAO was not available in the secondary study. Most of these metabolites have been associated with CHD or CHD risk factors before. 11, 13, [29] [30] [31] Valine has been associated with metabolic risk factors, 30 insulin resistance, 32 incident type 2 diabetes, 31 and future cardiovascular events. 11 Ornithine is produced by splitting of urea from arginine, resulting in a lower bioavailability of arginine. Arginine is necessary to produce nitric oxide, which is essential for a normal Figure 1 The subset of signals selected using 10-fold cross-validated LASSO regression and their coefficients in the primary study (left panel) and the secondary study (right panel).
endothelial function. 29 This pathway has been linked to CHD 10 and CHD mortality. 29 The presence of glucose and 1,5-anhydrosorbitol, a short-term marker for glycemic control, 33 could indicate that our metabolite score marks individuals at higher risk for developing diabetes or insulin resistance and thereby CHD. Low creatinine levels are a marker for high HDL-C and low low-density lipoprotein cholesterol levels. 34 Thus, the presence of creatinine and an unsaturated lipid structure could indicate that our metabolite risk score is a marker for an unfavorable lipid profile. This is confirmed by the proportion of variance explained by HDL-C and TC levels, 7.9% and 16.4%. In the secondary study, these explained variances are only 0.9% and 4.6%, but this discrepancy might be caused by statin treatment, resulting in lower cholesterol levels for the cases compared with controls. A secondary explanation for the incorporation of creatinine in the metabolite score is that elevated creatinine levels may indicate kidney dysfunction, which is associated with cardiovascular disease. 35 Increased TMAO levels have been associated with cardiovascular risk before. 13, 36 Thus, it seems that the LASSO procedure selected relevant metabolites that have been associated with CHD and CHD risk factors before.
Several issues have to be resolved before it can be concluded if a metabolomic approach is useful for CHD risk prediction. First, the known, quantifiable serum metabolome consists of 4,229 metabolites, 37 of which only 36 (0.9%) were included in this study. Other studies that use 1 H-NMR spectroscopy also incorporated lipoproteins.
11,12 Therefore, we hope that we can achieve better in follow-up studies when incorporating H-NMRdetermined lipoproteins in addition to low-molecularweight metabolites in our analysis. Moreover, other metabolomic platforms should be also be included. 37 Second, the 16 signals provided by our study should be measured in large prospective cohorts for replication and to determine universally applicable weights. The current Figure 2 The proportion of variance in the metabolite score explained by TRFs in the primary study (upper panel) and the secondary study (lower panel).
study is too small for that purpose. Third, we had nonfasting samples in the primary study and fasted samples in the secondary study. However, we still found that the 1 H-NMR signals selected in the primary nonfasted study were also associated with prevalent CHD in the fasted secondary study. This indicates that we have selected 1 H-NMR signals that are robust whether fasted or nonfasted samples are used. Fourth, constructing robust prediction models constitutes a statistical challenge, especially in a high-dimensional setting. In our case, model selection by LASSO regression resulted in predictor selection that eliminated high correlations among predictors. This can lead to reduced transferability of prediction models as correlation structures of predictors can vary between studies. A wide variety of penalized regression models are available (eg, elastic net, ridge regression), and further research is needed to select the appropriate methods for the application at hand.
Conclusion
A metabolite score derived from a single point metabolome measurement is associated with the risk of CHD independent of TRFs but does not improve risk prediction beyond TRFs. On the other hand, LASSO regression resulted in the selection of relevant metabolites, suggesting that more comprehensive metabolomic methods may be promising tools to further improve upon CHD disease understanding and risk stratification. Data are expressed as mean ± SD or % (n). ⁎ Univariate OR was calculated per unit increase for age, total cholesterol, HDL-C, SBP, BMI, and for the categorical traits. † All the variables were added into 1 multivariable logistic regression model.
Appendix. A metabolomic profile is associated with the risk of incident coronary heart disease Supplementary materials and methods
Acquisition and processing of 1 H-NMR spectra
All proton nuclear magnetic resonance ( 1 H-NMR) experiments were acquired on a 600-MHz Bruker Avance II spectrometer (Bruker BioSpin, Karlsruhe, Germany) equipped with a 5-mm triple resonance inverse (TCI) cryogenic probe head with Z-gradient system and automatic tuning and matching. All experiments were recorded at 310K. Temperature calibration was done before each batch of measurements using the method of Findeisen et al. 38 The duration of the π/2 pulses were automatically calibrated for each individual sample using a homonuclear-gated nutation experiment on the locked and shimmed samples after automatic tuning and matching of the probe head. 39 The stored EDTA plasma and serum samples were thawed at 4°C and were mixed by inverting the tubes 10 times. Next, samples (300 μL) were mixed with 300 μL 75 mM disodium phosphate buffer in For water suppression, presaturation of the water resonance with an effective field of γB 1 = 25 Hz was applied during the relaxation delay.
40 J-resolved spectra (JRES) 41 were recorded with a relaxation delay of 2 seconds and a total of 1 scan for each increment in the indirect dimension. A data matrix of 40 × 12,288 data points was collected covering a sweep width of 78 × 10,000 Hz. A sine-shaped window function was applied, and the data were zero-filled to 256 × 16,384 complex data points before Fourier transformation. The resulting data matrix was tilted along the rows by shifting each row (k) by 0.4992 * (128 − k) points and symmetrized about the central horizontal lines to compensate for the skew of the multiplets in the F1 dimension. For T2-filtered 38 H NMR spectra, a standard 1D Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence, 42 ,43 was used with a relaxation delay of 4 seconds. A pulse train of 128 refocusing pulses with individual spin echo delays of 0.6 ms were applied resulting in a total T2 filtering delay of 78 ms. A total of 73,728 data points covering a spectral width of 12,019 Hz were collected using 16 scans. The Free Induction Decay (FID) was zero-filled to 131,072 complex data points, and an exponential window function was applied with a line broadening factor of 1.0 Hz before Fourier transformation. The spectra were automatically phased and baseline corrected.
Quality control, scaling, and calibration of the 1 H-NMR spectra
Further data processing was performed in Matlab (R2009a; The Mathworks, Inc, Natick, MA). The spectra and associated data were converted into Matlab files using in-house code. First, the spectra were combined into 1 file while removing superfluous information. For CPMG, this included dropping the imaginary part of the spectrum, whereas for the JRES spectra, the sum projection along the indirect dimension was taken. Quality control on the set of 1 H NMR spectra was carried out by examining a set of spectroscopic parameters such as shim values and intensity of the water signal and subsequently visually inspecting the spectra. The spectra that failed the quality control were not included for further analysis. The spectra were then scaled with respect to the sensitivity of the receiver coil, as determined from the pulse length that was automatically calibrated for each sample. 44 After subtracting a constant value as a simple baseline correction, the spectra were calibrated with respect to the anomeric resonance of α-Dglucose (δ = 5.23 ppm). 45 Because there are small deviations of the peak position in the different 1 H-NMR spectra, alignment was performed using the correlation optimized warping algorithm by Tomasi et al. 46 This was performed actively for the CPMG spectra, after which the same warping was applied to the JRES projection. Peaks in the JRES projection were picked by finding the signals that were above the surrounding spectral area by more than the estimated noise level. Peaks in different spectra were grouped according to similarity in peak position and intensity. The intensity and the position give good initial guesses for the deconvolution of the peaks by fitting groups of mixed Gaussian-Lorentzian line shapes to isolated spectral areas using a Simplex optimization algorithm. As the fitting algorithm incidentally fails to converge properly, values further from the median than 3 times the interquartile range are discarded. Using partial least squares regression, the remaining peak intensities Tables  5  Supplementary Table I  5  Supplementary Table II  17  Supplementary Table III  18  Supplementary Table IV  19  Supplementary Table V  20  Supplementary Table VI  21  Supplementary Table VII  23  Supplementary Table VIII  24  Supplementary Figure  25  References  26 were used to build a linear model that predicts all intensities directly from the nonwarped spectrum, yielding also values for the cases where the peak picking failed or the deconvolution values were discarded, and eliminating the problem of faulty warping.
For 76 signals, metabolites were assigned using information from previously reported plasma/serum metabolites, 43 For reclassification, the following risk categories were used: 0% to b5%, 5% to b10%, 10% to b20%, ≥20%. ⁎ The TRFs include age in years, TC, HDL-C, SBP, BMI, gender, current smoking, self-reported diabetes, and parental history of MI.
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Supplementary For calculating the NRI, the following risk categories were used: 0% to b5%, 5% to b10%, 10% to b20%, ≥20%. Abbreviations: P Up, proportion of participants placed into a higher risk category; P Down, proportion of participants placed into a lower risk category.
Supplementary Table VI Abbreviations: MS, Metabolite score; Diff, difference. ⁎ Difference in C-indices. † Difference in C-indices between the metabolite score only and the traditional risk factor(s) and the metabolite score combined. Odds ratios were calculated per SD increase in metabolite score. ⁎ The metabolite score was adjusted for age, TC, HDL-C, SBP, BMI, sex, smoking, diabetes, and parental history of MI.
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